RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity

RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity

Abstract Background Endocrine-resistant breast cancers have elevated expression of XBP1, where it drives endocrine resistance by controlling the expression of its target genes. Despite the in-depth understanding of the biological functions of XBP1 in ER-positive breast cancer, effectors of endocrine...

Full description

Bibliographic Details
Main Authors: David Barua, Afrin Sultana, Md Nahidul Islam, Fergus Cox, Ananya Gupta, Sanjeev Gupta
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
XBP1
Endocrine resistance
RRM2
CDC6
Breast cancer
ER stress
Online Access:https://doi.org/10.1186/s12885-023-10745-1

Internet

https://doi.org/10.1186/s12885-023-10745-1

Similar Items